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1Galectin-3 (Gal-3) is a galactoside-binding lectin, which interacts with several extracellular matrix proteins, car-
bohydrates, and nonglycosylated proteins.1 A correlation 
between Gal-3 expression and fibrosis has been found in sev-
eral tissues: Gal-3 is upregulated in cases of liver, renal, and 
idiopathic pulmonary fibrosis.2,3 Gal-3 is localized within the 
cytoplasmic space, but it can be translocated into the nucleus 
or secreted outside the plasma membrane via a nonclassical 
mechanism by several cell types.1 In particular, macrophages 
can secrete Gal-3 in the extracellular space and activate resting 
fibroblasts into a matrix-producing phenotype.2 Sharma et al4 
have shown that intrapericardial infusion of Gal-3 in healthy 
rats induces reduction in left ventricular (LV) ejection frac-
tion and increase in collagen content. Furthermore, cardiac 
hypertrophy and dysfunction after angiotensin II infusion or 
transverse aortic constriction are blunted in Gal-3 knockout 
mice compared with wild-type, and Gal-3 pharmacological 
inhibition by N-acetyllactosamine inhibits progression of LV 
remodeling in mice submitted to transverse aortic constric-
tion.5 Therefore, Gal-3 is likely involved in myocardial fibro-
genesis in animal models of heart failure (HF) and participates 
in the mechanisms of cardiac remodeling.
The renin–angiotensin–aldosterone system plays as well 
a fundamental role in HF pathophysiology,6 and the use of 
renin–angiotensin–aldosterone system antagonists represents 
a cornerstone in HF therapy.7 Aldosterone infusion in rats 
with high-salt intake yields myocardial fibrosis via mineralo-
corticoid receptor (MR), which is preceded by macrophage 
infiltration and enhanced expression of inflammatory mark-
ers, such as osteopontin and monocyte chemoattractant pro-
tein-1.8 Despite evidences on the role of oxidative stress and 
inflammation in the initiation of aldosterone-mediated cardiac 
fibrosis, the molecular machinery leading to end-organ dam-
age remains largely unknown.9
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Although not conclusive, there is some experimental evi-
dence that renin–angiotensin–aldosterone system and Gal-3 
share signaling pathways in the development of cardiac fibrosis. 
In a model of double transgenic mice, with overexpression of 
both cardiac aldosterone synthase and the renin gene (AS-Ren 
mice), Azibani et al10 showed that cardiac hyperaldosteronism in 
AS-Ren was associated with a massive macrophage infiltration, 
and with higher Gal-3 expression and protein level, compared 
with Ren mice, Gal-3 being more abundant in the fibrotic areas. 
Recently, Calvier et al11 observed an aldosterone-upregulated 
Gal-3 expression in cultured vascular smooth muscle cells. They 
showed that administration of aldosterone and salt induced vas-
cular hypertrophy, inflammation, fibrosis, and enhanced aortic 
Gal-3 expression in hypertensive rats.11 Noteworthy, these effects 
were antagonized by either MR antagonists or by modified cit-
rus pectin (MCP), a water soluble indigestible polysaccharide 
binding to Gal-3 and blocking its activity through specific car-
bohydrate recognition domains.12,13 Moreover, MCP has been 
demonstrated to prevent cardiac and renal damage when coad-
ministered with aldosterone and salt in rats.14
Nonetheless, although a role of Gal-3 in the process of 
fibrogenesis and remodeling is clear, the evidence of its 
involvement in the aldosterone-mediated end-organ damage is 
still scarce in animal models of LV dysfunction and HF. The 
aim of this study was, therefore, to investigate the interaction 
of aldosterone and Gal-3 in pathophysiological mechanisms 
leading to HF in a murine model of LV systolic dysfunction.
Methods
Animals
Experimentations were conducted in agreement with the standards of 
animal care (National Institutes of Health Guide for the Care and Use 
of Laboratory Animals). Animal work was approved by the French 
National Committee of Ethic Reflexion on Animal Experimentation 
(CNREEA number, 09).
Transgenic mice with cardiac-specific overexpression of the al-
dosterone synthase gene (AS mice) were used for the experimental 
protocol. As previously reported, AS mice overexpress the AS gene 
in cardiomyocytes and have a 2-fold increased aldosterone concen-
tration in the heart.15 All mice were viable and were studied at 3 to 
5 months.
Induction of LV Systolic Dysfunction and Treatment
To induce LV systolic dysfunction, mice were treated with isoprotere-
nol subcutaneous injections (300 mg/kg BID for 2 consecutive days). 
Echocardiography was performed again 1 day after the last injection. 
On the same day, AS mice were randomly assigned to receive treat-
ment with either placebo (ISO group, n=12), the MR inhibitor potas-
sium canrenoate (30 mg/kg per day as drinking water; ISO+C group, 
n=9), the Gal-3 pharmacological inhibitor MCP (100 mg/kg per day 
as drinking water; ISO+M group, n=10), or both canrenoate and MCP 
(ISO+C+M group, n=10). Echocardiography was performed again 7 
and 14 days after the last isoproterenol injection. Mice were eutha-
nized immediately thereafter. A group of mice injected with vehicle 
instead of isoproterenol and with no further pharmacological treat-
ment served as control (control group, n=8).
Echocardiography
Mice underwent baseline transthoracic echocardiography using a GE 
Vivid 7 machine (General Electric Company, Fairfield, CT) equipped 
with an 8- to 14-MHz linear transducer during light anesthesia with 
isofluorane (1%), as previously described.10 Hearts were imaged in 
the 2-dimensional parasternal short-axis view, and 3 different frames 
of an M-mode echocardiogram of the midventricle were recorded 
at the papillary muscle level. Each frame was analyzed to measure 
wall thickness and LV end-diastolic and LV end-systolic internal 
diameters. LV fractional shortening was calculated as (LV end-dia-
stolic internal diameter−LV end-systolic internal diameter)/LV end-
diastolic internal diameter and was taken as an index of LV systolic 
performance. All measurements were performed in a blinded fashion.
Organ Weight and Tissue Analysis
Mice were euthanized by an overdose of pentothal, and the hearts 
were arrested in diastole by KCl (30 mmol/L), quickly rinsed in cold 
saline, and blotted. Body weight, heart weight, weights of lung and 
liver, and tibia lengths were determined. The heart was transversally 
divided into 2 parts: the base part was embedded into Tissue-Tek 
O.C.T. (Sakura Finetek, Villeneuve d’Ascq, France) and frozen in 
liquid nitrogen for further histological and immunohistochemical 
analyses, and the apical part was snap frozen in liquid nitrogen. All 
samples were stored at −80°C until further analysis.
For measures of cardiac fibrosis, equatorial cryostat sections (7 
μm) of the ventricles were stained with the collagen-specific pic-
rosirius red stain (0.5% in saturated picric acid). Stained sections 
were observed under polarized light, and acquired images were used 
for the measure of collagen area/total ventricular surface ratio on 
at least 5 fields per sections, 3 sections per heart, and n>5 animals 
per groups. All images were acquired on a Leica microscope (Leica 
Microsystems, Rueil Malmaison, France) and recorded for further 
analysis. All the measures were performed in a blinded fashion using 
the IPLab software (BD Biosciences, San Jose, CA). Images were as-
sembled using Photoshop (Adobe Systems, San Jose, CA).
Western blot and immunofluorescence analyses were performed as 
published.10
Gene Expression Analysis
For quantitative reverse transcription polymerase chain reaction anal-
yses, total RNA extraction from the LVs, reverse transcription, and 
quantitative polymerase chain reaction were performed as previously 
described.10 mRNA levels for genes of interest were normalized to the 
GAPDH mRNA levels and expressed as the relative change compared 
with the control samples.
Figure 1. Effects of aldosterone and galectin-3 antagonism on 
left ventricular systolic function. A, Schematic representation of 
the experimental protocol, including induction of left ventricular 
dysfunction and treatment regimens. B, Isoproterenol (ISO) 
induced a decrease in left ventricular fractional shortening (FS) 
1 day after injections compared with baseline in all mice. Mice 
treated with canrenoate (ISO+C), modified citrus pectin (MCP; 
ISO+M), or both (ISO+C+M) showed a marked increase in FS 
compared with mice treated with ISO only (ISO) 1 week and 2 
weeks after ISO injections; *P<0.001 vs ISO and †P<0.05 vs 
ISO+M. Ctrl indicates control.
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Statistics
Results are presented as mean±SEM, computed from the average 
measurements obtained from each group of animals. Differences 
among >2 experimental conditions were tested by the 1-way ANOVA 
test, followed by the Bonferroni test to analyze differences between 
groups. The Mann–Whitney U test was used to assess statistical dif-
ferences between 2 experimental conditions. Shapiro–Wilk test was 
used to assess normality. Statistical analyses were performed with 
IBM SPSS software, version 19.0. P<0.05 was considered significant.
Results
Gal-3 and Aldosterone Inhibition Reverses LV 
Remodeling and Systolic Dysfunction
The isoproterenol-treated AS mice (ISO group) showed a sig-
nificant reduction in LV fractional shortening at day 1, which 
was maintained up to day 14 (Figure 1). Acute mortality after 
isoproterenol injection reached 10%. The ISO group showed 
increased LV end-systolic internal diameter and stable LV 
end-diastolic internal diameter after isoproterenol injections. 
The effects of isoproterenol were maintained up to 14 days. 
Treatment with either canrenoate or MCP (ISO+C and ISO+M 
groups, respectively) induced a decrease in LV end-systolic 
internal diameter and an increase in fractional shortening up to 
baseline values (Table S1 in the online-only Data Supplement). 
Similar results were observed when mice were treated with both 
canrenoate and MCP (ISO+C+M group; Figure 1; Table S1).
Gal-3 and Aldosterone Inhibition Prevents 
Myocardial Hypertrophy and Interstitial Fibrosis
At sacrifice, mice treated with either canreonate or MCP 
showed less cardiac hypertrophy, as estimated by heart weight/
Figure 2. Galectin-3 and aldosterone antagonism reduces myocardial fibrosis. A, Sirius red staining in mice treated with placebo 
(control [Ctrl]), isoproterenol (ISO), ISO+either canrenoate (ISO+C) or modified citrus pectin (MCP; ISO+M), or both canrenoate and MCP 
(ISO+C+M) showing lower degree of myocardial fibrosis (arrows) in animals treated with aldosterone or galectin-3 antagonists.  
B, Computer-assisted evaluation showed complementary effects of canrenoate and MCP on the extent of fibrotic tissue; *P<0.05 vs ISO; 
$$P<0.01 vs Ctrl.
Figure 3. Galectin-3 and aldosterone pharmacological inhibition reduce cardiac galectin-3 expression and protein content. A, Treatment 
with canrenoate (ISO+C), modified citrus pectin (ISO+M), or both (ISO+C+M) decreased galectin-3 gene expression, estimated as mRNA 
content, compared with treatment with isoproterenol only (ISO). B, Similar results were obtained when galectin-3 protein content was 
evaluated by Western blot. C, Galectin-3 immunoblotting revealed significant accumulation in subendocardial areas (green) in ISO mice, 
which was abolished in ISO+C, ISO+M, and ISO+C+M groups; *P<0.05 vs ISO; $P<0.05 vs control (Ctrl).
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tibia length ratio. The ISO+C+M group exhibited even lower 
values of heart weight/tibia length compared with either 
ISO+C or ISO+M groups, thus suggesting a complementary 
effect of aldosterone and Gal-3 blockade in preventing myo-
cardial hypertrophy (Table S2). Finally, all treatment groups 
showed lower organ congestion (as evaluated by lung and liver/
tibia length ratios), with the ISO+C+M group demonstrating 
the lowest values of liver weight/tibia length ratio (Table S2).
As shown in Figure 2A and 2B, treatment with isopro-
terenol mainly resulted in the development of interstitial 
fibrosis (arrows). Treatment with canreonate or MCP reduced 
the amount of fibrotic tissue in heart sections. The develop-
ment of myocardial fibrosis was further blunted when mice 
were treated with Gal-3 antagonist in combination with MR 
blocker, thus supporting a role for Gal-3 as a mediator of pro-
fibrotic pathways in LV dysfunction.
Effects of Aldosterone and Gal-3 Inhibition on 
Myocardial Gal-3 Expression and Protein Content
To test the effects of different pharmacological approaches on 
myocardial Gal-3, cardiac Gal-3 gene expression was evalu-
ated by quantitative reverse transcription polymerase chain 
reaction (Figure 3A). In accordance with the myocardial 
inflammation and fibrogenesis elicited by high-dose isoproter-
enol,16 ISO mice showed a markedly enhanced Gal-3 expres-
sion. MR antagonism significantly reduced Gal-3 expression 
(−64% versus ISO). Noteworthy, treatment with MCP alone 
or in combination with canrenoate was also associated with 
Figure 4. Effects of canrenoate and modified citrus pectin on inflammatory markers. A and B, A reduced expression of monocyte 
chemoattractant protein-1 (MCP-1) and CD68 was observed in mice treated with canrenoate (ISO+C) or modified citrus pectin (ISO+M) 
compared with mice treated with isoproterenol only (ISO); a more pronounced decrease was observed in the group treated with both 
canrenoate and MCP (ISO+C+M). C, CD68 immunolabeling revealed low accumulation (green areas) in ISO+M and even lower in ISO+C 
and ISO+C+M groups, compared with ISO; *P<0.05 vs ISO and $P<0.05 vs control (Ctrl).
Figure 5. Effects of canrenoate and modified citrus pectin on profibrotic markers. A and B, Treatment with canrenoate (ISO+C), modified 
citrus pectin (ISO+M), or their combination (ISO+C+M) induced a reduction in collagen 1 and collagen 3 gene expression, estimated as 
Coll1 and Coll3 mRNA content. C, A decrease in Coll1/Coll3 ratio was also observed in treatment groups, being more pronounced in 
ISO+M and ISO+C+M mice; *P<0.05 vs ISO; $$P<0.01 vs control (Ctrl). ISO indicates isoproterenol.
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decreased myocardial Gal-3 expression (−47% and −55% 
versus ISO, respectively), raising the possibility that Gal-3 
may further stimulate—via a positive feedback—its own 
expression.
The Gal-3 protein content in cardiac tissue was also 
assessed through Western blot analysis (Figure 3B), thus 
showing lower Gal-3 in hearts from ISO+C, ISO+M, and 
ISO+C+M mice (−69%, −61%, and −76%, respectively) com-
pared with ISO. Furthermore, immunolabeling (Figure 3C) 
revealed a significant accumulation of Gal-3 in subendocar-
dial areas (which are likely the most prone to the develop-
ment of isoproterenol-induced damage) of ISO mice, whereas 
it was undetectable in samples from other treatment groups, 
thus supporting an inhibitory effect of canreonate and MCP 
on Gal-3 beyond the transcriptional level.
Gal-3 and Aldosterone Inhibition Decreases 
Isoproterenol-Induced Inflammatory  
and Profibrotic Response
Compared with hearts of the ISO group, mice treated with 
either canreonate or MCP exhibited signs of a blunted 
inflammatory response, as indicated by lower levels of MCP-
1 and CD68 mRNAs (Figure 4A and 4B). The expression of 
these genes, both involved in macrophage recruitment and 
activation, was further decreased by combined treatment, sug-
gesting a complementary effect of Gal-3 antagonism over MR 
blockade. In line with results from reverse transcription poly-
merase chain reaction, indirect immunolabeling for CD-68 
showed reduced positive cells in hearts from mice assigned to 
pharmacological treatment (ISO+C, ISO+M, and ISO+C+M) 
compared with ISO (Figure 4C).
We also tested whether the inhibitory effects of Gal-3 and 
MR blockade on inflammatory response were associated with 
decreased fibrotic drive on myocardium through the analysis 
of the expression pattern of collagen I (Coll 1) and collagen 
III (Coll 3), 2 key structural components of the extracellular 
matrix. Expression of Coll 1 was lower in hearts from mice 
treated with canreonate, MCP, or their combination (−67%, 
−78%, and −75% versus ISO, respectively; Figure 5A). As 
concerns Coll 3, ISO+C and ISO+M mice showed a significant 
reduction in gene expression compared with ISO mice (−53% 
and −45%, respectively), whereas canrenoate+MCP exhibited 
only a modest decrease (−21%; Figure 5B). Because the rela-
tive increase of stiffer collagen phenotype (type I) to that of 
more elastic type (type III) is a feature of LV remodeling in 
dilated cardiomyopathy,17–19 we finally evaluated the Coll 1/Coll 3 
expression ratio. Although the ratio was lower in ISO+C com-
pared with ISO (−13%), treatment with MCP alone or together 
with canreonate yielded a more pronounced reduction in 
Coll 1/Coll 3 ratio (−52% and −48%, respectively; Figure 5C).
Interestingly, ISO+C, ISO+M, and ISO+C+M groups also 
showed a similar, marked decrease in brain natriuretic peptide 
gene expression (Figure 6).
Discussion
Gal-3 and aldosterone antagonism reversed isoproterenol-
induced LV systolic dysfunction and prevented the develop-
ment of myocardial fibrosis in this mice model with selective 
Figure 6. Effects of canrenoate and modified citrus pectin 
on brain natriuretic peptide (BNP) expression. Treatment with 
canrenoate (ISO+C), modified citrus pectin (ISO+M), or their 
combination (ISO+C+M) induced a marked reduction in BNP 
gene expression, estimated as Bnp mRNA content; *P<0.05 vs 
ISO and $P<0.05 vs control (Ctrl). ISO indicates isoproterenol.
Figure 7. Putative model of aldosterone–galectin-3 (Gal-3) interplay in the development of myocardial fibrosis. Further to a downstream 
effect after aldosterone-mediated macrophage activation, Gal-3 may be released as a consequence of different stimuli (including 
ischemia and inflammation). Similarly, aldosterone is likely to promote fibrosis through other Gal-3–independent mechanisms (such as 
oxidative stress, calcium overload, or increase in plasminogen activator inhibitor type 1 [PAI1]). Such alternative profibrotic pathways may 
explain the complementary effects observed on myocardial hypertrophy, inflammation, and fibrosis with combined aldosterone and Gal-3 
antagonism. CD68 indicates cluster of differentiation 68; MCP, modified citrus pectin; and MCP-1, monocyte chemoattractant protein-1.
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cardiac hyperaldosteronism. Furthermore, combined Gal-3 
and aldosterone blockade resulted in enhanced effects on car-
diac inflammation and fibrosis, as well as on LV hypertrophy 
with respect to MCP or canrenoate alone.
Aldosterone has been largely studied as a mediator of car-
diovascular remodeling in HF, and activation of MR is a crucial 
step in cellular and molecular machinery leading to myocardial 
inflammation, fibrosis, cardiomyocyte necrosis, and LV hyper-
trophy.20 Nonetheless, despite this growing body of evidence, the 
exact mechanisms involved in aldosterone detrimental actions 
are still to be completely elucidated. More recently, Gal-3 has 
been reported to mediate inflammation and fibrosis and to hold 
a significant value in HF pathophysiology and prognostic strati-
fication. The interaction between aldosterone and Gal-3 in the 
development of cardiovascular remodeling has been supported 
by recent experimental evidences from both animal and human 
studies. In particular, aldosterone has been demonstrated to 
induce Gal-3 secretion by macrophages through MR via the 
phosphoinositide 3-kinase inhibitor/Akt and nuclear factor-κB 
transcription signaling pathways.21 In line with these findings, 
treatment with MR antagonists has been shown to downregu-
late cardiac expression of Gal-3 after experimental myocardial 
infarction.22 Moreover, Calvier et al14 have reported that cardiac 
and renal fibrosis is prevented by either pharmacological antag-
onisms (MCP) or genetic disruption of Gal-3 in rodents treated 
with aldosterone and salt, showing LV diastolic dysfunction.
Our findings support a role for Gal-3 in the development 
of fibrosis and dysfunction after cardiac injury. Furthermore, 
consistently with the presence of an interaction between aldo-
sterone and Gal-3–mediated cardiac damage, we report a 
decrease in Gal-3 gene expression and protein content in mice 
treated with the MR antagonist canreonate.
High-dose isoproterenol, a sympathomimetic nonselec-
tive β-adrenergic receptor agonist, was used to induce LV 
dysfunction. Previous studies have demonstrated that iso-
proterenol produces diffuse, graded myocardial fibrosis in a 
patchy pattern, while maintaining a patent coronary vascula-
ture,23,24 likely subsequent to acute contraction band lesions.25 
Moreover, rodents submitted to isoproterenol subcutaneous 
injections show progressive LV remodeling, with impairment 
of both systolic and diastolic LV functions.24,26 We, there-
fore, tested the effects of aldosterone and Gal-3 antagonism 
in an HF model associated with diffuse myocardial damage 
and cardiac hyperaldosteronism, in the absence of discrete 
myocardial infarction or afterload increase, as for the case 
of coronary artery ligation and transverse aortic constriction, 
respectively,25 thus resembling clinical nonischemic dilated 
cardiomyopathy.
Treatment with MCP improved LV systolic function in 
AS mice after isoproterenol administration. This is the first 
demonstration that pharmacological inhibition of Gal-3 can 
reverse established systolic dysfunction and LV remodeling 
and further supports the potential clinical utility of targeting 
Gal-3 in HF therapy, through a tailored approach based on the 
evaluation of circulating levels of Gal-3.
Although the effects of aldosterone-induced macrophage 
activation and Gal-3 release are expected to be antagonized 
to the same extent by MCP, canreonate, or their combina-
tion, our findings on the effects on cardiac hypertrophy and 
myocardial inflammation and fibrosis with MCP+canreonate 
administration are consistent with a complementary action of 
Gal-3 and MR blockade. Such observations may be explained 
by other Gal-3–independent mechanisms of fibrosis, known to 
be promoted by aldosterone, such as the induction of oxidative 
stress,9 intracellular calcium accumulation,27 or the increase in 
plasminogen activator inhibitor type 1.28 Furthermore, cardiac 
expression and secretion of Gal-3 may be induced by other 
factors independent from MR activation, as ischemia and pro-
inflammatory stimuli (Figure 7).29–31
Perspectives
We demonstrate for the first time that pharmacological inhibi-
tion of Gal-3 can reverse isoproterenol-induced LV dysfunc-
tion in a murine model of HF with cardiac hyperaldosteronism, 
by reducing the development of myocardial inflammation and 
fibrogenesis in a complementary fashion over MR blockade. 
Our results only support an interaction between Gal-3 and 
aldosterone in the development of LV remodeling in HF, but 
further experiments will be needed to clarify the cellular and 
molecular basis underlying such interaction and to assess the 
potential utility of Gal-3 inhibition as a promising therapeutic 
option in HF, as an adjunct to conventional pharmacological 
neurohormonal antagonism, including the use of MR blockers.
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What Is New?
•	Galectin-3 and aldosterone interact in the development of left ventricular 
inflammation, fibrosis, and remodeling in a murine model of left ven-
tricular dysfunction.
•	Pharmacological inhibition of galectin-3 can reverse left ventricular sys-
tolic dysfunction after treatment with isoproterenol in mice.
What Is Relevant?
•	This study shows that galectin-3 is involved in the mechanisms of aldo-
sterone-induced myocardial damage and supports a role for galectin-3 
inhibition as a future therapeutic option in heart failure.
Summary
Pharmacological inhibition of galectin-3 reduces the extent of myo-
cardial inflammation and fibrosis in a complementary fashion over 
mineralocorticoid receptor blockade and reverses left ventricular 
dysfunction in a murine model of isoproterenol-induced heart failure.
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 INHIBITION OF GALECTIN-3 PATHWAY PREVENTS ISOPROTERENOL-INDUCED LEFT VENTRICULAR 
DYSFUNCTION AND FIBROSIS IN MICE 
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Short title: Inhibition of galectin-3 in LV dysfunction 
 Supplemental Table S1. Left ventricular diameters in mice. 
Left ventricular end-diastolic (LVEDD) and end-systolic (LVESD) diameters at baseline, and 1, 7 and 14 days 
(D1, D7 and D14, respectively) after the last isoproterenol injection in mice treated with isoproterenol only 
(ISO), or isoproterenol followed by canrenoate (ISO+C), modified citrus pectin (ISO+M) or 
canreonate+modified citrus pectin (ISO+C+M); * p<0.001 vs ISO, † p<0.05 vs ISO. 
 
 
LV diameters Baseline D1 D7 D14 
ISO     
LVEDD (mm) 4.1 ± 0.1 4.0 ± 0.1 4.0 ± 0.1 4.0 ± 0.1 
LVESD (mm) 2.7 ± 0.1 2.9 ± 0.1 2.9 ± 0.1 2.9 ± 0.1 
ISO+C     
LVEDD (mm) 3.8 ± 0.1 3.8 ± 0.1 3.8 ± 0.1 3.7 ± 0.1 
LVESD (mm) 2.3 ± 0.1 2.8 ± 0.1 2.3 ± 0.0* 2.2 ± 0.1* 
ISO+M     
LVEDD (mm) 4.1 ± 0.1 4.0 ± 0.1 4.0 ± 0.1 3.9 ± 0.1 
LVESD (mm) 2.6 ± 0.1 2.9 ± 0.1 2.6 ± 0.1† 2.4 ± 0.1* 
ISO+C+M     
LVEDD (mm) 4.0 ± 0.1 3.9 ± 0.1 4.0 ± 0.1 3.8 ± 0.0 
LVESD (mm) 2.4 ± 0.1 2.8 ± 0.1 2.4 ± 0.1* 2.2 ± 0.0* 
 Supplemental Table S2. Body and organ weight in mice. 
Whole body, and heart, lung and liver weights corrected for tibia lenght in mice treated with saline (Ctrl), 
isoproterenol (ISO), and isoproterenol plus canrenoate (ISO+C), modified citrus pectin (ISO+M) or 
canreonate+modified citrus pectin (ISO+C+M); * p<0.05 vs ISO. 
 
 
Variable Ctrl ISO ISO+C ISO+M ISO+C+M 
Body weight (g) 27.6 ± 0.3 27.9 ± 0.8 26.4 ± 1.2 27.6 ± 1.2 26.8 ± 1.0 
Heart weight/tibia lenght 
(mg/mm) 
5.4 ± 0.1 
 
6.3 ± 0.2 5.7 ± 0.2 5.7 ± 0.2 5.3 ± 0.1* 
Lung weight/tibia lenght 
(mg/mm) 
6.8 ± 0.4 7.8 ± 0.3 7.1 ± 0.3 7.2 ± 0.3 7.4 ± 0.3 
Liver weight/tibia lenght 
(mg/mm) 
80.0 ± 3.0 82.4 ± 1.8 79.0 ± 3.9 75.1 ± 3.6 69.6 ± 1.3* 
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